Related Experiment Videos
Nephrotoxicity of semustine.
Cancer Treatment Reports
|December 1, 1983
Summary
Semustine, a chemotherapy drug, can cause severe kidney damage (nephrotoxicity) and failure. High cumulative doses over 1200 mg/m2 increase this risk, with potential delayed onset of renal dysfunction.
Area of Science:
- Oncology
- Nephrology
- Pharmacology
Background:
- Semustine is an investigational chemotherapy agent.
- Long-term administration of semustine has been linked to nephrotoxicity and renal failure.
Purpose of the Study:
- To analyze the incidence, dose-response, and clinical manifestations of semustine-induced nephrotoxicity.
- To investigate the potential mechanisms underlying semustine nephrotoxicity.
Main Methods:
- A comprehensive review of 29 published cases and six unpublished cases of semustine nephrotoxicity.
- Analysis of clinical and histological data, treatment duration, and cumulative dosage.
Main Results:
- A high risk of severe nephrotoxicity was observed when the cumulative dose of semustine exceeded 1200 mg/m2.
- A significant delay in the onset of renal dysfunction was noted in some patients.
- Clinical and histological findings associated with semustine nephrotoxicity were characterized.
Conclusions:
- Cumulative semustine doses exceeding 1200 mg/m2 pose a substantial risk for severe nephrotoxicity.
- Clinicians should be aware of the potential for delayed renal dysfunction in patients receiving semustine.
- Further research into the mechanisms of semustine nephrotoxicity is warranted.